Peter J. Ruane, M.D., Inc.

Quick facts

Marketed products

• Raltegravir and Atazanavir · Infectious Disease / Virology
  This combination inhibits HIV replication by blocking integrase (raltegravir) and protease (atazanavir), preventing viral DNA integration and polyprotein processing.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Peter J. Ruane, M.D., Inc. portfolio CI brief
• Peter J. Ruane, M.D., Inc. pipeline updates RSS